Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label follow-on study of certolizumab pegol plus methotrexate in rheumatoid arthritis
2005-001350-24Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoint: ACR20 response. Started Apr 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-001350-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001350-24.